CO2018002510A2 - Estructura peptídica que se une a factor de crecimiento endotelial vascular a construida con bucles de cistina, composiciones y procedimientos de elaboración - Google Patents

Estructura peptídica que se une a factor de crecimiento endotelial vascular a construida con bucles de cistina, composiciones y procedimientos de elaboración

Info

Publication number
CO2018002510A2
CO2018002510A2 CONC2018/0002510A CO2018002510A CO2018002510A2 CO 2018002510 A2 CO2018002510 A2 CO 2018002510A2 CO 2018002510 A CO2018002510 A CO 2018002510A CO 2018002510 A2 CO2018002510 A2 CO 2018002510A2
Authority
CO
Colombia
Prior art keywords
cystine
compositions
loops
constructed
growth factor
Prior art date
Application number
CONC2018/0002510A
Other languages
English (en)
Inventor
Rami Hannoush
Harini Kaluarachchi
Aaron NILE
Cameron Noland
Yingnan Zhang
Lijuan Zhou
Xinxin Gao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CO2018002510A2 publication Critical patent/CO2018002510A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/63—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan péptidos de nudo de cistina (CKP) de origen no natural que se unen a VEGF-A. Además, se proporcionan métodos para utilizar los CKP de origen no natural que se unen a VEGF-A, incluidas compossiciones y métodos de diagnóstico y terapéuticos. También se proporcionan CKP de origen no natural que se unen a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (LRP6).
CONC2018/0002510A 2015-09-15 2018-03-07 Estructura peptídica que se une a factor de crecimiento endotelial vascular a construida con bucles de cistina, composiciones y procedimientos de elaboración CO2018002510A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219063P 2015-09-15 2015-09-15
PCT/US2016/052012 WO2017049009A1 (en) 2015-09-15 2016-09-15 Cystine knot scaffold platform

Publications (1)

Publication Number Publication Date
CO2018002510A2 true CO2018002510A2 (es) 2018-05-31

Family

ID=57068206

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0002510A CO2018002510A2 (es) 2015-09-15 2018-03-07 Estructura peptídica que se une a factor de crecimiento endotelial vascular a construida con bucles de cistina, composiciones y procedimientos de elaboración

Country Status (23)

Country Link
US (7) US10428125B2 (es)
EP (1) EP3350215A1 (es)
JP (2) JP7166916B2 (es)
KR (1) KR20180052718A (es)
CN (3) CN114805528A (es)
AR (1) AR106032A1 (es)
AU (2) AU2016323445B2 (es)
BR (1) BR112018002263A2 (es)
CA (1) CA2996006A1 (es)
CL (2) CL2018000668A1 (es)
CO (1) CO2018002510A2 (es)
CR (1) CR20180169A (es)
HK (1) HK1253318A1 (es)
IL (2) IL257399B (es)
MA (1) MA42828A (es)
MX (1) MX2018002922A (es)
MY (1) MY190552A (es)
PE (1) PE20181293A1 (es)
PH (1) PH12018500577A1 (es)
RU (1) RU2770384C2 (es)
TW (1) TWI799366B (es)
UA (1) UA125505C2 (es)
WO (1) WO2017049009A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
KR20230023727A (ko) 2020-06-11 2023-02-17 제넨테크, 인크. 나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US918814A (en) 1907-10-30 1909-04-20 Handy Mfg Company Funnel.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CA2404528A1 (en) 2000-03-31 2001-10-04 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
EP1290169A2 (en) 2000-06-01 2003-03-12 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1404297B1 (en) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
WO2003029275A2 (en) 2001-10-03 2003-04-10 Regeneron Pharmaceuticals, Inc. Anti-angiogenic peptides
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
NZ560504A (en) 2005-01-24 2009-07-31 Pepscan Systems Bv Binding compounds, immunogenic compounds and peptidomimetics
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20090305994A1 (en) 2005-06-29 2009-12-10 D Andrea Lucas Domenico Compounds Modulating Vegf Receptor and Uses Thereof
CA2622441A1 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
WO2007131050A2 (en) 2006-05-02 2007-11-15 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
WO2008070479A2 (en) 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
EP2187968A4 (en) 2007-08-21 2013-02-20 Univ Texas THERMOKINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS
EP2604280A3 (en) * 2008-03-27 2013-10-16 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2010048588A2 (en) * 2008-10-23 2010-04-29 Massachusetts Institute Of Technology Directed engagement of activating fc receptors
KR101698362B1 (ko) * 2008-11-03 2017-01-20 몰리큘라 파트너스 아게 Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
US20110207653A1 (en) 2009-12-21 2011-08-25 Adrian Raiche Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent
CN102740830A (zh) 2009-12-23 2012-10-17 普西维达公司 缓释递送装置
US8339139B2 (en) * 2010-01-29 2012-12-25 Infineon Technologies Ag System and method for testing a circuit
EP2638173B1 (en) * 2010-11-08 2019-06-19 The Board of Trustees of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2012112969A1 (en) * 2011-02-18 2012-08-23 Endo Pharmaceuticals Inc. Aminoindane compounds and use thereof in treating pain
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
JP2015528454A (ja) * 2012-08-28 2015-09-28 ノバルティス アーゲー 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用
GB201218278D0 (en) * 2012-10-11 2012-11-28 Cyclogenix Ltd Translocating peptide
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺

Also Published As

Publication number Publication date
US11155586B2 (en) 2021-10-26
US20170129927A1 (en) 2017-05-11
EP3350215A1 (en) 2018-07-25
RU2018113442A3 (es) 2020-02-17
MX2018002922A (es) 2018-06-07
HK1253318A1 (zh) 2019-06-14
AU2021204400A1 (en) 2021-07-22
CN108026162A (zh) 2018-05-11
KR20180052718A (ko) 2018-05-18
US10428125B2 (en) 2019-10-01
CA2996006A1 (en) 2017-03-23
JP2022130481A (ja) 2022-09-06
CR20180169A (es) 2018-04-24
US11078243B2 (en) 2021-08-03
WO2017049009A8 (en) 2018-02-22
US20200140498A1 (en) 2020-05-07
UA125505C2 (uk) 2022-04-13
US20230174596A1 (en) 2023-06-08
AU2016323445A1 (en) 2018-03-01
AU2021204400B2 (en) 2023-02-02
CN114591422A (zh) 2022-06-07
TW201717993A (zh) 2017-06-01
AR106032A1 (es) 2017-12-06
RU2770384C2 (ru) 2022-04-15
IL257399B (en) 2022-08-01
CL2020001781A1 (es) 2020-10-23
PH12018500577A1 (en) 2018-10-15
CN108026162B (zh) 2022-04-05
RU2018113442A (ru) 2019-10-16
US10696721B2 (en) 2020-06-30
IL257399A (en) 2018-04-30
MA42828A (fr) 2018-07-25
US20200325187A1 (en) 2020-10-15
CL2018000668A1 (es) 2018-07-20
US20180291069A1 (en) 2018-10-11
MY190552A (en) 2022-04-27
US20200115424A1 (en) 2020-04-16
US20200231636A1 (en) 2020-07-23
US11407794B2 (en) 2022-08-09
WO2017049009A1 (en) 2017-03-23
IL294568A (en) 2022-09-01
JP7166916B2 (ja) 2022-11-08
PE20181293A1 (es) 2018-08-07
CN114805528A (zh) 2022-07-29
JP2018533912A (ja) 2018-11-22
TWI799366B (zh) 2023-04-21
AU2016323445B2 (en) 2021-04-01
BR112018002263A2 (pt) 2018-09-18

Similar Documents

Publication Publication Date Title
MX2020004883A (es) Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales.
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
ECSP18005520A (es) Anticuerpos de factor xi y métodos de uso
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
CO2018002510A2 (es) Estructura peptídica que se une a factor de crecimiento endotelial vascular a construida con bucles de cistina, composiciones y procedimientos de elaboración
PE20161390A1 (es) Anticuerpos multiespecificos
EA201691078A1 (ru) Терапевтические пептиды
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
EA201792245A1 (ru) Биоконъюгаты и их применения
CO2019006073A2 (es) Estructura cristalina de gremlina 1 y anticuerpo inhibidor
CL2019003211A1 (es) Anticuerpos anti-garp-tgf-ß.
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
PE20151808A1 (es) Peptidos terapeuticos
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
BR112019008349A2 (pt) composição de peptídeos, e, utilização de uma composição.
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
AR093620A1 (es) Anticuerpos bmp-6
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR095334A1 (es) Composiciones nutricionales que contienen un componente peptídico con propiedades estimulantes de la adiponectina y método para promover un peso corporal saludable